Serum Galectin-3 Is Elevated in Obesity and Negatively Correlates with Glycosylated Hemoglobin in Type 2 Diabetes

Weigert, Johanna; Neumeier, Markus; Wanninger, Josef; Bauer, Sabrina; Farkas, S.; Scherer, Marcus N.; Schnitzbauer, Andreas A.; Schäffler, Andréas; Aslanidis, Charalampos; Schölmerich, Jürgen; Buechler, Christa

doi:10.1210/jc.2009-1619

Cited by 164 publications

(153 citation statements)

References 39 publications

Supporting

Mentioning

129

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, increased plasma galectin-3 levels have been reported in (metastasized) cancer [4,5,13,14,[28][29][30]], Behçet's disease [7] and obesity [8], and galectin-3 levels may even guide therapy [14]. We hypothesize that deleterious signals that precede overt disease initiate subclinical tissue changes associated with galectin-3 activation and secretion.…”

Section: Discussionmentioning

confidence: 96%

See 1 more Smart Citation

The fibrosis marker galectin‐3 and outcome in the general population

Boer¹,

Veldhuisen²,

Gansevoort³

et al. 2011

Journal of Internal Medicine

341

291

View full text Add to dashboard Cite

Abstract. de Boer RA, van Veldhuisen DJ, Gansevoort RT, Muller Kobold AC, van Gilst WH, Hillege HL, Bakker SJL, van der Harst P (University of Groningen). The fibrosis marker galectin-3 and outcome in the general population. J Intern Med 2012; 272: 55-64.Objective. Galectin-3 is involved in fibrosis and inflammation and plays a role in heart failure, renal disease, obesity and cancer. We aimed to establish the relationship between galectin-3 and cardiovascular (CV) risk factors and mortality in the general population.Design and subjects. This study included 7968 subjects from the Prevention of REnal and Vascular ENd-stage Disease (PREVEND) cohort, with a median follow-up of approximately 10 years. Plasma galectin-3 was measured in baseline samples.Main outcome measures. We investigated the relationships between galectin-3 levels, demographic characteristics and risk factors of CV disease. We determined the prognostic value for all-cause, CV and cancer mortality.Results. The mean age of the population was 50 ± 13 years. Mean blood pressure was 129 ⁄ 74 mmHg, mean cholesterol was 5.7 ± 1.1 mmol L )1 and median galectin-3 was 10.9 ng mL )1 [interquartile range (IQR) 9.0-13.1]. Galectin-3 levels correlated with a wide range of risk factors of CV disease, including blood pressure, serum lipids, body mass index, renal function and N-terminal pro-B-type natriuretic peptide (P < 0.0001). We observed a strong association between galectin-3 and age. Furthermore, we found a gender interaction, with female subjects (n = 4001) having higher median galectin-3 levels (11.0 ng mL )1 , IQR 9.1-13.4 vs. men (n = 3967) 10.7 ng mL )1 , IQR 8.9-12.8; P < 0.0001), and galectin-3 levels in women more strongly correlated with risk factors of CV disease. After correction for the classical CV risk factors (smoking, blood pressure, cholesterol and diabetes), galectin-3 levels independently predicted all-cause mortality (hazard ratio per SD galectin-3 1.09, 95% CI 1.01-1.19; P = 0.036), but not CV and cancer mortality separately.Conclusions. Galectin-3 is associated with age and risk factors of CV disease, with a strong gender interaction for these correlations. Galectin-3 predicts all-cause mortality in the general population.

show abstract

Section: Discussionmentioning

confidence: 96%

“…In addition, galectin-3 plays a systemic role in inflammatory and proliferation responses [1][2][3][4]. In line with this, galectins have been implicated in various diseases, particularly in cancer [5,6], immunological disorders [3,4,7] and common multifactor cardiovascular (CV) disease such as obesity [8] and heart failure (HF) [9].…”

Section: Introductionmentioning

confidence: 95%

The fibrosis marker galectin‐3 and outcome in the general population

Boer¹,

Veldhuisen²,

Gansevoort³

et al. 2011

Journal of Internal Medicine

341

291

View full text Add to dashboard Cite

show abstract

“…Moreover, galectin-3 levels were found to be higher in subjects with obesity or type 2 diabetes [40] and a cross-sectional survey showed that high galectin-3 values were associated with micro-and macrovascular complications in diabetic patients [41]. Thus, the higher galectin-3 levels in diabetic individuals and in general in those with dysmetabolic disorders might mark the increased susceptibility of these subjects toward heart failure, though longitudinal studies of adequate size and duration specifically testing this hypothesis are needed.…”

Section: Introductionmentioning

confidence: 97%

Galectin-3 in diabetic patients

Pugliese

Iacobini

Ricci

et al. 2014

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Galectin-3 is a versatile molecule which exerts several and sometimes opposite functions in various pathophysiological processes. Recently, galectin-3 has gained attention as a powerful predictor of heart failure and mortality, thus becoming a useful prognostic marker in clinical practice. Moreover, though not specifically investigated in diabetic cohorts, plasma levels of galectin-3 correlated with the prevalence of diabetes and related metabolic conditions, thus suggesting that pharmacological blockade of this lectin might be successful for treating heart failure especially in subjects suffering from these disorders. Indeed, galectin-3 is considered not only as a marker of heart failure, but also as a mediator of the disease, due to its pro-fibrotic action, though evidence comes mainly from studies in galectin-3 deficient mice. However, these studies have provided contrasting results, with either attenuation or acceleration of organ fibrosis and inflammation, depending on the experimental setting and particularly on the levels of advanced glycation endproducts (AGEs)/advanced lipoxidation endproducts (ALEs), of which galectin-3 is a scavenging receptor. In fact, under conditions of increased AGE/ALE levels, galectin-3 ablation was associated with tissue-specific outcomes, reflecting the AGE/ALE-receptor function of this lectin. Conversely, in experimental models of acute inflammation and fibrosis, galectin-3 deficiency resulted in attenuation of tissue injury. There is a need for prospective studies in diabetic patients specifically investigating the relation of galectin-3 levels with complications and for further animal studies in order to establish the effective role of this lectin in organ damage before considering its pharmacological blockade in the clinical setting.

show abstract

“…However, the role of Gal-3 in type 2 diabetes remains incompletely understood. The Gal-3 levels are increased in the sera of obese subjects and negatively correlate with the levels of glycosylated haemoglobin (24). In contrast with these data, Okhura et al reported that low serum Gal-3 levels are associated with insulin resistance and T2DM (25).…”

Section: Gojaznost I Tip 2 Diabetes Mellitusa (T2dm) Predstavljaju Vementioning

confidence: 90%

“…Galectin-3 (Gal-3) is a β-galactoside-binding lectin that is expressed in different tissues and cells and plays an important role in obesity, T2DM and inflammation (17,18,19). Gal-3 regulates inflammation and adipogenesis, and this lectin is expressed in adipocytes and infiltrating immune cells in the adipose tissue (20).…”

Section: Introductionmentioning

confidence: 99%

Galectin-3 Deletion Enhances Visceral Adipose Tissue Inflammation and Dysregulates Glucose Metabolism in Mice on a High-Fat Diet

Jeftic

Kovačević

Jovičić

et al. 2016

Serbian Journal of Experimental and Clinical Research

View full text Add to dashboard Cite

Obesity and type 2 diabetes mellitus (T2DM) constitute major health problems worldwide. Increased visceral adiposity enhances the risk of insulin resistance and type 2 diabetes. e mechanisms involved in obesity-associated chronic infl ammation in metabolic tissues (metafl ammation) that lead to insulin resistance and dysregulated glucose metabolism are incompletely defi ned. Galectin-3 (Gal-3), a β-galactosidebinding lectin, modulates immune/infl ammatory responses and specifi cally binds to metabolic danger molecules. To dissect the role of

show abstract

Serum Galectin-3 Is Elevated in Obesity and Negatively Correlates with Glycosylated Hemoglobin in Type 2 Diabetes

Abstract: Systemic galectin-3 is elevated in obesity and negatively correlates with glycated hemoglobin in T2D patients, pointing to a modifying function of galectin-3 in human metabolic diseases.

Cited by 164 publications

References 39 publications

The fibrosis marker galectin‐3 and outcome in the general population

The fibrosis marker galectin‐3 and outcome in the general population

Galectin-3 in diabetic patients

Galectin-3 Deletion Enhances Visceral Adipose Tissue Inflammation and Dysregulates Glucose Metabolism in Mice on a High-Fat Diet

Contact Info

Product

Resources

About